hengrui glp-1 In a Phase 3 program reported by Kailera Therapeutics and partner Jiangsu Hengrui, two China trials of the oral small-molecule receptor agonist HRS-7535 met their primary goals in obesity and in China's Hengrui/Kailera duo just filed
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



























